Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions

Table 3

Comparison of commonly used regimens for recurrent Ewing sarcoma.

	Cyclophosphamide + topotecan	Temozolomide + irinotecan	High-dose ifosfamide	Ifosfamide + carboplatin + etoposide
Number of patients	66	58	37	22
Author (Ref)	Saylors et al. [13]; Hunold et al. [14]	Casey et al. [36]; Wagner et al. [35]; Anderson et al. [44]	Ferrari et al. [23]	Van Winkle et al. [47]
Primary toxicity	Myelosuppression	Gastrointestinal	Myelosuppression	Myelosuppression
Alopecia	Yes	Uncommon	Yes	Yes
Myeloid growth factor	Yes	Rarely	Yes	Yes
IV access required	Generally	Optional if administered orally	Yes	Yes
Home administration	Uncommon	Common	No	No
Response rates (complete + partial)	33–35%	29–63%	34%	48%